Bismuth therapy in gastrointestinal diseases.

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Bismuth therapy is a recognized treatment for peptic ulcer disease and various forms of diarrhea.
• It demonstrates comparable efficacy to H2-receptor antagonists for peptic ulcers, with added benefits of lower cost and reduced relapse rates.
• Bismuth compounds exhibit antimicrobial properties against Helicobacter pylori, particularly when combined with antibiotics.

Purpose of the Study:

• To review the efficacy and safety of bismuth therapy in managing gastrointestinal disorders.
• To assess the role of bismuth in treating peptic ulcer disease and diarrhea, including traveler's diarrhea.
• To evaluate the potential for bismuth toxicity and establish safe treatment guidelines.

Main Methods:

• Review of existing literature on bismuth therapy for gastrointestinal conditions.
• Analysis of studies investigating bismuth's efficacy, particularly in combination with antibiotics for Helicobacter pylori eradication.
• Examination of data regarding bismuth absorption, tissue sequestration, and associated neurological toxicity.

Main Results:

• Bismuth therapy is effective for peptic ulcers and diarrhea, with combination therapy showing promise for H. pylori eradication.
• Bismuth subsalicylate is effective for traveler's diarrhea and pediatric diarrhea.
• Neurological toxicity, though rare, has been associated with prolonged use of certain bismuth compounds, prompting safety recommendations.

Conclusions:

• Bismuth compounds offer a cost-effective treatment option for specific gastrointestinal disorders.
• Safe usage necessitates limiting treatment duration to 6-8 weeks, followed by 8-week bismuth-free intervals to mitigate heavy metal accumulation.
• Further research may explore optimized bismuth formulations and treatment regimens.